pyrvinium has been researched along with Adenomatous Polyposis Coli in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Burlingame, O; Capobianco, AJ; Fei, DL; Flaveny, CA; Giambelli, C; Han, L; Hang, BI; Lee, E; Li, B; Nose, V; Orton, D; Pei, XH; Robbins, DJ | 1 |
| Cselenyi, CS; Ghidu, VP; Hang, BI; Hanson, AJ; Jernigan, KK; Kim, K; LaFleur, B; Lee, E; Lee, LA; Melancon, B; Meyers, KC; Miller, DM; Orton, D; Salic, A; Schneider, J; Sulikowski, GA; Tahinci, E; Thorne, CA; Waterson, AG | 1 |
2 other study(ies) available for pyrvinium and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.
Topics: Adenomatous Polyposis Coli; Animals; Antineoplastic Agents; Cell Survival; Drug Approval; Drug Repositioning; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Mice, Inbred C57BL; Mice, Transgenic; Pyrvinium Compounds; Wnt Signaling Pathway | 2014 |
Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli; Animals; Axin Protein; beta Catenin; Casein Kinase I; Casein Kinase Ialpha; Cell Extracts; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Oocytes; Pyrvinium Compounds; Repressor Proteins; Signal Transduction; Wnt Proteins; Xenopus laevis; Xenopus Proteins | 2010 |